Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Bellevue city councilmember John Stokes will ... for people with disabilities on Friday, June 21 ... , The exhibit hall, which is free and ... will feature leading manufacturers and suppliers of assistive ... technologies, computer applications, and home modification equipment. Local ...
(Date:6/19/2013)... , June 19, 2013  U.S. Secretary of ... ceremony at which distinguished Syngenta  scientist Mary-Dell ... prestigious 2013 World Food Prize. The prize is the ... development by improving the quality, quantity or availability of ... two other laureates were recognized for "revolutionary biotechnology discoveries ...
(Date:6/19/2013)... Clinverse, Inc. , a ... trials, today announced it will be exhibiting and ... in Boston, June 24-26, 2013. Clinverse’s eClinical ... fully configurable, cloud-based clinical financial lifecycle system. , ... Clinverse’s eClinical Commerce Network, automates site contract set-up ...
(Date:6/19/2013)... , June 19, 2013 MO BIO ... and other challenging microbial nucleic acid purification, announces ... Kit, for extraction of pure protein from all ... coincides with the 20 th anniversary of ... capabilities. (Photo: http://photos.prnewswire.com/prnh/20130619/LA32633 ) ...
Breaking Biology Technology:City of Bellevue, Wash., Welcomes Assistive Technology Exhibit Hall 2Syngenta's Mary-Dell Chilton named 2013 World Food Prize laureate 2Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2MO BIO Laboratories, Inc. launches the first kit for protein extraction from soil 2
... Improve PCR product yield and specificity for difficult ... Reactions with,Perfect Match PCR Enhancer , ... PCR amplification systems produce multiple product bands or,products ... events, template secondary,structures, or suboptimal PCR conditions. Stratagenes ...
... copy number , High-Titer,Retroviral Vectors for ... C. Bauer Peter Vaillancourt ,Stratagene , The high-titer ... any,Moloney Murine Leukemia Virus (MMLV)-based packaging cell line. Virus ... wide range of cell types including,human cells, and because ...
... Phosphatase useful for dephosphorylation serine,threonine or tyrosine ... Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... dualspecificity protein,phosphatase that has been produced as ... calmodulinbinding peptide. The tag simplifies purification of ...
Cached Biology Technology:Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 2Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 3Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 4Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 5Optimizing pfuturbo DNA Polymerase Amplification Reactions with,Perfect Match PCR Enhancer 6High-Titer ,Retroviral Vectors for Gene Delivery 2High-Titer ,Retroviral Vectors for Gene Delivery 3High-Titer ,Retroviral Vectors for Gene Delivery 4High-Titer ,Retroviral Vectors for Gene Delivery 5High-Titer ,Retroviral Vectors for Gene Delivery 6High-Titer ,Retroviral Vectors for Gene Delivery 7High-Titer ,Retroviral Vectors for Gene Delivery 8Highly Active and Removable AffinityTagged Lambda Phosphatase 2Highly Active and Removable AffinityTagged Lambda Phosphatase 3Highly Active and Removable AffinityTagged Lambda Phosphatase 4
(Date:6/19/2013)... The Flemish plant scientist Marc Van Montagu (born 1933) ... with the American scientists Mary-Dell Chilton and Robert T. ... by the US Secretary of State, John Kerry. The ... and agriculture" - gives the award annually to one ... social importance for the quality, quantity or availability of ...
(Date:6/19/2013)... birds are threatened with extinction as a result of rising ... The Ohio State University in the US. Their work is ... the human population will continue to pose a threat to ... be a threshold above which population growth would cease to ... in Springer,s journal, Human Ecology . , It has ...
(Date:6/19/2013)... of Pittsburgh has developed antibacterial compounds, derived from ... potential treatments for drug-resistant bacterial infections and appear ... quite small, making them inexpensive and easy to ... 2013 issue of the journal Antimicrobial Agents ... probable applications will likely be the chronic bacterial ...
Breaking Biology News(10 mins):World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 3World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 4Are we pushing animals over the edge? 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... blighting the Horn of Africa brings with it an ... are yet to eradicate the scourge of poverty or ... the world,s most desperate people. In her new ... Challenges, Interventions and Preventive Measures, published in collaboration with ...
... DigitalPersona, Inc. , a global provider of authentication and ... fingerprint biometric Civil ID solutions at this ... Supported by the National Institute of Standards and Technology ... Consortium Conference is focused on biometric technologies for Defense, ...
... 2011 An analysis of two decades of data ... Analysis (FIA) program shows that the live volume of ... infestations of hemlock woolly adelgid that have decimated local ... Update co-authored by scientists from two U.S. Forest Service ...
Cached Biology News:Water and sanitation related diseases and the environment 2DigitalPersona Showcases Fingerprint Biometrics for Civil ID Applications at the Biometric Consortium Conference 2DigitalPersona Showcases Fingerprint Biometrics for Civil ID Applications at the Biometric Consortium Conference 3US Forest Service study finds hemlock still abundant despite adelgid infestation 2
Purified anti-PXR...
Request Info...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: